184 related articles for article (PubMed ID: 15967080)
41. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
[TBL] [Abstract][Full Text] [Related]
42. [Ki-67 proliferative index in non-Hodgkin's lymphoma and its clinical significance].
Li J; Hu R; Liao AJ; Shi HY; Yan W; Liu ZG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):935-9. PubMed ID: 21867618
[TBL] [Abstract][Full Text] [Related]
43. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
44. Machine learning-based classification of diffuse large B-cell lymphoma patients by eight gene expression profiles.
Zhao S; Dong X; Shen W; Ye Z; Xiang R
Cancer Med; 2016 May; 5(5):837-52. PubMed ID: 26869285
[TBL] [Abstract][Full Text] [Related]
45. Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases.
Tzankov A; Pehrs AC; Zimpfer A; Ascani S; Lugli A; Pileri S; Dirnhofer S
J Clin Pathol; 2003 Oct; 56(10):747-52. PubMed ID: 14514777
[TBL] [Abstract][Full Text] [Related]
46. C-MYC overexpression predicts aggressive transformation and a poor outcome in mucosa-associated lymphoid tissue lymphomas.
Huang W; Guo L; Liu H; Zheng B; Ying J; Lv N
Int J Clin Exp Pathol; 2014; 7(9):5634-44. PubMed ID: 25337204
[TBL] [Abstract][Full Text] [Related]
47. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
Horn H; Ziepert M; Becher C; Barth TF; Bernd HW; Feller AC; Klapper W; Hummel M; Stein H; Hansmann ML; Schmelter C; Möller P; Cogliatti S; Pfreundschuh M; Schmitz N; Trümper L; Siebert R; Loeffler M; Rosenwald A; Ott G;
Blood; 2013 Mar; 121(12):2253-63. PubMed ID: 23335369
[TBL] [Abstract][Full Text] [Related]
48. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.
Peng W; Wu J; Feng J
Clin Exp Med; 2017 Feb; 17(1):1-8. PubMed ID: 26475621
[TBL] [Abstract][Full Text] [Related]
49. Improved personalized survival prediction of patients with diffuse large B-cell Lymphoma using gene expression profiling.
Mosquera Orgueira A; Díaz Arias JÁ; Cid López M; Peleteiro Raíndo A; Antelo Rodríguez B; Aliste Santos C; Alonso Vence N; Bendaña López Á; Abuín Blanco A; Bao Pérez L; González Pérez MS; Pérez Encinas MM; Fraga Rodríguez MF; Bello López JL
BMC Cancer; 2020 Oct; 20(1):1017. PubMed ID: 33087075
[TBL] [Abstract][Full Text] [Related]
50. Red blood cell distribution width and platelet counts are independent prognostic factors and improve the predictive ability of IPI score in diffuse large B-cell lymphoma patients.
Li M; Xia H; Zheng H; Li Y; Liu J; Hu L; Li J; Ding Y; Pu L; Gui Q; Zheng Y; Zhai Z; Xiong S
BMC Cancer; 2019 Nov; 19(1):1084. PubMed ID: 31711453
[TBL] [Abstract][Full Text] [Related]
51. Transcriptome integration analysis and specific diagnosis model construction for Hodgkin's lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma.
Li WX; Dai SX; An SQ; Sun T; Liu J; Wang J; Liu LG; Xun Y; Yang H; Fan LX; Zhang XL; Liao WQ; You H; Tamagnone L; Liu F; Huang JF; Liu D
Aging (Albany NY); 2021 Apr; 13(8):11833-11859. PubMed ID: 33885377
[TBL] [Abstract][Full Text] [Related]
52. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
[TBL] [Abstract][Full Text] [Related]
53. Detection and possible prognostic relevance of p53 gene mutations in diffuse large B-cell lymphoma. An analysis of 51 cases and review of the literature.
Kerbauy FR; Colleoni GW; Saad ST; Regis Silva MR; Correa Alves A; Aguiar KC; Albuquerque DM; Kobarg J; Seixas MT; Kerbauy J
Leuk Lymphoma; 2004 Oct; 45(10):2071-8. PubMed ID: 15370252
[TBL] [Abstract][Full Text] [Related]
54. Gene expression-based risk score in diffuse large B-cell lymphoma.
Bret C; Klein B; Moreaux J
Oncotarget; 2012 Dec; 3(12):1700-10. PubMed ID: 23482333
[TBL] [Abstract][Full Text] [Related]
55. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.
Alencar AJ; Malumbres R; Kozloski GA; Advani R; Talreja N; Chinichian S; Briones J; Natkunam Y; Sehn LH; Gascoyne RD; Tibshirani R; Lossos IS
Clin Cancer Res; 2011 Jun; 17(12):4125-35. PubMed ID: 21525173
[TBL] [Abstract][Full Text] [Related]
56. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma.
Barrans SL; Carter I; Owen RG; Davies FE; Patmore RD; Haynes AP; Morgan GJ; Jack AS
Blood; 2002 Feb; 99(4):1136-43. PubMed ID: 11830458
[TBL] [Abstract][Full Text] [Related]
57. Investigation of expressions of PDK1, PLK1 and c-Myc in diffuse large B-cell lymphoma.
Feng Y; Lin J; Liu Y; Tang Y; Zhou Y; Zhong M
Int J Exp Pathol; 2019 Feb; 100(1):32-40. PubMed ID: 30912195
[TBL] [Abstract][Full Text] [Related]
58. Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals.
Chang CC; Kampalath B; Schultz C; Bunyi-Teopengco E; Logan B; Eshoa C; Dincer AP; Perkins SL
Arch Pathol Lab Med; 2003 Feb; 127(2):208-12. PubMed ID: 12562237
[TBL] [Abstract][Full Text] [Related]
59. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas.
Zhang A; Ohshima K; Sato K; Kanda M; Suzumiya J; Shimazaki K; Kawasaki C; Kikuchi M
Pathol Int; 1999 Dec; 49(12):1043-52. PubMed ID: 10632924
[TBL] [Abstract][Full Text] [Related]
60. Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells.
Andréasson U; Dictor M; Jerkeman M; Berglund M; Sundström C; Linderoth J; Rosenquist R; Borrebaeck CA; Ek S
Am J Hematol; 2009 Dec; 84(12):803-8. PubMed ID: 19844990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]